RWJ-51204

Source: Wikipedia, the free encyclopedia.
RWJ-51204
Identifiers
  • 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5] imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide
JSmol)
  • Fc1ccccc1NC(=O)C=3C(=O)CCN4c2c(cc(F)cc2)N(C=34)COCC
  • InChI=1S/C21H19F2N3O3/c1-2-29-12-26-17-11-13(22)7-8-16(17)25-10-9-18(27)19(21(25)26)20(28)24-15-6-4-3-5-14(15)23/h3-8,11H,2,9-10,12H2,1H3,(H,24,28) checkY
  • Key:VQOQDABVGWLROX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

RWJ-51204 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

RWJ-51204 is a nonselective

GABAA receptors.[1] It produces primarily anxiolytic effects at low doses, with sedative, ataxia and muscle relaxant effects only appearing at some 20x the effective anxiolytic dose.[2] It was discovered by researchers at the pharmaceutical company Johnson & Johnson,[3][4]
but its development has been discontinued.

References

  1. PMID 12871032
    .
  2. S2CID 23880756
    .
  3. ^ US 5817668, Reitz AB, Jordan AD, Sanfilippo PJ, Vavouyios-Smith A, issued 6 October 1998, assigned to Ortho Pharma Corp 
  4. doi:10.1021/op990182l
    .


drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=RWJ-51204&oldid=1084240936"